• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

avitamedical

Avita begins Recell manufacturing in new facility

August 23, 2018 By Sarah Faulkner

Avita Medical (ASX:AVH) said today that it successfully finished multiple production runs for its Recell device at its newly-acquired manufacturing facility in Ventura, California. Avita acquired the facility last month from a manufacturer that previously assembled the Recell device on a contract basis. The components being made at the Ventura facility will be used to support the […]

Filed Under: Regenerative Medicine, Wound Care Tagged With: avitamedical

Avita Medical wins expanded FDA compassionate use IDE for Recell

August 9, 2018 By Fink Densford

Avita Medical (ASX:AVH) said today it won expanded coverage under the FDA’s compassionate use investigational device exemption program for its Recell autologous cell harvesting device. The ReCell autologous cell harvesting device is designed to use the patient’s own skin cells to treat a variety of skin issues, including burns, reconstructive and cosmetic procedures, Avita said. With […]

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Regenerative Medicine Tagged With: avitamedical

ViewRay picks up ex-Spectranetics CEO Drake, COO Matin | Personnel Moves – July 25, 2018

July 25, 2018 By Fink Densford

ViewRay (NSDQ:VRAY) said yesterday it tapped former Spectranetics head Scott Drake as its new chief executive officer and former Spectranetics COO Shar Matin as its new COO. Before joining ViewRay, Drake served as CEO and prez of Spectranetics, which was acquired by Royal Philips (NYSE:PHG) in a deal that closed last August. Drake also serves as board chair […]

Filed Under: Business/Financial News Tagged With: Alphabet (Google), avitamedical, Bonesupport, Clinical Innovations, intentsolutions, ohiomedical, Olympus, Personnel Moves, Philips, Procyrion, Spectranetics Corp., ViewRay Inc.

Avita Medical touts publication of pivotal ReCell trial data

June 26, 2018 By Fink Densford

Avita Medical (ASX:AVH) today released results from a pivotal clinical trial of its ReCell autologous cell harvesting device in treating deep partial-thickness second-degree burns. The ReCell autologous cell harvesting device is designed to use the patient’s own skin cells to treat a variety of skin issues, including burns, reconstructive and cosmetic procedures, Avita said. Results from […]

Filed Under: Clinical Trials, Regenerative Medicine Tagged With: avitamedical

Avita raises $12m for US debut of Recell device

June 7, 2018 By Brad Perriello

Avita Medical (ASX:AVH) said yesterday that it raised $12.3 million to back the U.S. launch of its Recell wound treatment. Melbourne- and Valencia, Calif.-based Avita said the A$16 million round, raised from a consortium of institutional and “sophisticated” investors led by Bell Potter, consists of two tranches: $9.8 million (A$12.8 million) that’s slated to close June […]

Filed Under: Funding Roundup, Wall Street Beat, Wound Care Tagged With: avitamedical

Avita Medical touts pivotal trial of ReCell burn injury device

April 16, 2018 By Sarah Faulkner

Avita Medical (ASX:AVH) said today that a pivotal trial of its ReCell autologous cell harvesting device met its co-primary endpoints. The device, designed to help heal deep, full-thickness burns, demonstrated a statistically significant reduction in donor skin requirements compared to the standard of care and achieved comparable wound closure, Avita touted. Get the full story at […]

Filed Under: Clinical Trials, Wall Street Beat, Wound Care Tagged With: avitamedical

Avita touts ReCell use in treating flesh eating bacteria, announces Chinese trial

March 22, 2018 By Fink Densford

Avita Medical (ASX:AVH) this week announced that its ReCell technology had been used to treat a patient with necrotizing fasciitis, and that it launched a Chinese trial of the device exploring its use treating second-degree burns. The ReCell autologous cell harvesting device is designed to use the patient’s own skin cells to treat a variety of […]

Filed Under: Business/Financial News, Clinical Trials, Wound Care Tagged With: avitamedical

RenovaCare touts win in patent spat with Avita Medical

February 21, 2018 By Fink Densford

RenovaCare today touted a win in a patent spat with Avita Medical (ASX:AVH) after the US Patent Office dismissed a challenge to RenovaCare’s patents and denied a trial that Avita was seeking. RenovaCare said that the USPTO specifically noted that Avita’s arguments “were based on old claims and technologies which had already been considered and rejected,” […]

Filed Under: Legal News, Patent Infringement, Regenerative Medicine, Wound Care Tagged With: avitamedical, RenovaCare

Avita wins expanded FDA compassionate use for ReCell device

February 12, 2018 By Fink Densford

Avita Medical (ASX:AVH) said today the FDA approved an expansion to the number of patients treatable by its ReCell device under the compassionate use investigational device exemption program by 20 individuals. The ReCell autologous cell harvesting device is designed to use the patient’s own skin cells to treat a variety of skin issues, including burns, reconstructive and […]

Filed Under: Clinical Trials, Food & Drug Administration (FDA), Regenerative Medicine, Wound Care Tagged With: avitamedical

Avita Medical aims for $13m to bring ReCell burn injury device to U.S.

October 11, 2017 By Sarah Faulkner

Avita Medical (ASX:AVH) said today that it hopes to raise $13.2 million to fund its efforts to bring its ReCell autologous cell harvesting device for treatment of burn injuries to the U.S. The Australia-based company said it received commitments from investors for a $3.5 million private placement. Avita added that it plans to undertake a rights […]

Filed Under: Funding Roundup, Regenerative Medicine, Regulatory/Compliance, Wall Street Beat, Wound Care Tagged With: avitamedical

FDA expands protocol for investigational ReCell burn injury device

October 4, 2017 By Sarah Faulkner

Avita Medical (ASX:AVH) said today that the FDA approved a supplement to the company’s investigational device exemption for its ReCell autologous cell harvesting device. The approved treatment protocol for burn injuries has been simplified, according to the company, and the number of approved investigational sites has grown from eight to 15. Get the full story at […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Regenerative Medicine, Regulatory/Compliance, Wall Street Beat, Wound Care Tagged With: avitamedical

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS